Meeting Banner
Abstract #2517

eNOS-/- mice fed with HFD develop progressive non-alcoholic fatty liver disease (NAFLD) which is partially reversible with antihypertensive and hypoglycemic therapy

BegoƱa Lavin Plaza1, Marcelo E Andia2, Thomas Eykyn1, Alkystis Phinikaridou1, Aline Xavier2, and Rene M Botnar1

1Imaging Sciences and Biomedical Engineering, King's College London, London, United Kingdom, 2Radiology department, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile

Liver steatosis or non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. However, the cause and treatments are still controversial. Nitric oxide (NO) and its derivatives play important roles in the physiology and pathophysiology of the vascular system and liver metabolism. We quantified intraperitoneal fat and liver fat-fraction using 3T MRI in eNOS-/- mice fed with HFD and investigated (1) whether pharmacological treatments for type 2 diabetes and hypertension reduced fat deposition and (2) if the phenotype could be recapitulated by administration of an inhibitor of endothelial NO synthesis (L-NAME) in wild type mice.

This abstract and the presentation materials are available to members only; a login is required.

Join Here